Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,271Revenue $M31.0Net Margin (%)-641.6Altman Z-Score-10.2
Enterprise Value $M1,566EPS $-1.0Operating Margin %-489.4Piotroski F-Score4
P/E(ttm)--Beneish M-Score-2.9Pre-tax Margin (%)-642.2Higher ROA y-yY
Price/Book--10-y EBITDA Growth Rate %--Quick Ratio1.5Cash flow > EarningsY
Price/Sales35.65-y EBITDA Growth Rate %--Current Ratio1.5Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-59.1Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M225ROIC % (ttm)-138.7Gross Margin Increase y-yN

Gurus Latest Trades with EXEL

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
EXELCharles Brandes 2015-06-30 Buy $2.57 - $4.03
($3.24)
$ 5.6474%New holding25,400
EXELFirst Eagle Investment 2014-06-30 Sold Out $3.22 - $3.8
($3.45)
$ 5.6463%Sold Out0
EXELFirst Eagle Investment 2014-03-31 Reduce-0.01%$3.38 - $8.24
($6.84)
$ 5.64-18%Reduce 65.91%400,000
EXELFirst Eagle Investment 2012-09-30 Add0.02%$4.28 - $6.45
($5.29)
$ 5.647%Add 422.58%1,175,800
EXELFirst Eagle Investment 2012-03-31 Add$4.49 - $6.47
($5.14)
$ 5.6410%Add 125.00%225,000
EXELFirst Eagle Investment 2011-12-31 Buy $3.95 - $7.81
($5.01)
$ 5.6413%New holding100,000
EXELCarl Icahn 2011-09-30 Sold Out -0.43%$5.5 - $9.22
($7.34)
$ 5.64-23%Sold Out0
EXELFirst Eagle Investment 2011-03-31 Sold Out $7.22 - $12.45
($9.89)
$ 5.64-43%Sold Out0
EXELFirst Eagle Investment 2010-12-31 Buy 0.01%$3.98 - $9.08
($5.66)
$ 5.64-0%New holding280,000
EXELFirst Eagle Investment 2009-12-31 Sold Out -0.02%$5.33 - $8
($6.86)
$ 5.64-18%Sold Out0
EXELFirst Eagle Investment 2009-09-30 Buy 0.02%$4.4 - $6.99
($5.65)
$ 5.64-0%New holding274,700
EXELFirst Eagle Investment 2009-06-30 Sold Out -0.01%$4.16 - $5.55
($4.88)
$ 5.6416%Sold Out0
EXELFirst Eagle Investment 2009-03-31 Reduce$4.32 - $5.85
($4.8)
$ 5.6418%Reduce 25.67%144,800
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

EXEL is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


EXEL: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
MARCHESI VINCENT TDirector 2014-09-17Buy20,000$1.71229.82view
WILLSEY LANCEDirector 2013-08-29Buy10,000$5.159.51view
MARCHESI VINCENT TDirector 2012-12-20Buy4,000$4.6820.51view
MARCHESI VINCENT TDirector 2012-12-19Buy6,000$4.7219.49view
Schwab GiselaEVP and Chief Medical Officer 2012-12-10Buy25,000$4.3928.47view
MARCHESI VINCENT TDirector 2012-06-14Sell7,000$5.139.94view
RIVERA LUPE MEVP, Operations 2010-12-17Sell29,427$8.5-33.65view
RIVERA LUPE MEVP, Operations 2010-12-15Sell75,000$7.5-24.8view
Schwab GiselaEVP & Chief Medical Officer 2010-12-09Sell4,112$6.5-13.23view
WILLSEY LANCEDirector 2010-09-07Buy36,200$3.656.67view

Quarterly/Annual Reports about EXEL:

    News about EXEL:

    Articles On GuruFocus.com
    5-year lows: Synta Pharmaceuticals Inc, Exelixis Inc, Entropic Communications Inc, and Aeropostale I Dec 28 2014 
    5-year lows: National Presto Industries, Ennis Inc, Landauer Inc, and Exelixis Inc. Sep 28 2014 
    Weekly 3-Year Low Highlights: UAN, CLD, EXEL, QNST Sep 06 2014 
    Five-Year Lows: Rentech Nitrogen Partners LP, SandRidge Permian Trust, Millennial Media Inc., Exelix May 05 2014 
    5 Resilient Biotech Stocks to Buy for 2012 Feb 28 2012 
    Exelixis Inc. Reports Operating Results (10-K) Feb 22 2011 
    Exelixis Inc. (EXEL) CFO Frank Karbe buys 16,500 Shares Aug 25 2010 
    Exelixis Inc. Reports Operating Results (10-Q) Aug 05 2010 
    Exelixis Inc. Reports Operating Results (10-Q) May 11 2010 
    Exelixis Announces Second Quarter 2009 Financial Results Jul 30 2009 

    More From Other Websites
    Exelixis Up on Swiss Approval of Advanced Melanoma Drug Aug 28 2015
    Did Hedge Funds Sell Out Of Exelixis, Inc. (EXEL) Too Soon? Shares Jump On Regulatory Approval of... Aug 27 2015
    Exelixis (EXEL) Stock Climbs as Melanoma Treatment Gets Swiss Regulatory Approval Aug 27 2015
    Exelixis Announces First Regulatory Approval of Cobimetinib in Switzerland Aug 27 2015
    Exelixis Announces First Regulatory Approval of Cobimetinib in Switzerland Aug 27 2015
    Exelixis' Cancer Drug Gets Breakthrough Therapy Status Aug 25 2015
    EXELIXIS, INC. Financials Aug 25 2015
    FDA Grants Breakthrough Therapy Designation to Exelixis’ Cabozantinib for the Treatment of Renal... Aug 24 2015
    Data From METEOR Pivotal Trial of Cabozantinib in Advanced Renal Cell Carcinoma Accepted as... Aug 24 2015
    Data From METEOR Pivotal Trial of Cabozantinib in Advanced Renal Cell Carcinoma Accepted as... Aug 24 2015
    FDA Grants Breakthrough Therapy Designation to Exelixis’ Cabozantinib for the Treatment of Renal... Aug 24 2015
    Make Room for Exelixis in Your Portfolio Aug 12 2015
    Exelixis Posts Wider-Than-Expected Loss, Focus on Pipeline Aug 12 2015
    Edited Transcript of EXEL earnings conference call or presentation 11-Aug-15 9:00pm GMT Aug 12 2015
    Exelixis Inc Earnings Call scheduled for 5:00 pm ET today Aug 11 2015
    Exelixis reports 2Q loss Aug 11 2015
    Exelixis reports 2Q loss Aug 11 2015

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK